Section of Palliative Care and Medical Ethics, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA.
Palliative Research Center (PaRC), University of Pittsburgh, Pittsburgh, PA.
JCO Oncol Pract. 2022 Oct;18(10):e1594-e1602. doi: 10.1200/OP.22.00251. Epub 2022 Jul 25.
Stigma surrounding prescription opioids, or is increasingly recognized as a barrier to effective and guideline-concordant cancer pain management. Patients with advanced cancer report high rates of pain and prescription opioid exposure, yet little is known about how opioid stigma may manifest in this population.
We conducted in-depth qualitative interviews with 20 patients with advanced cancer and 11 support providers between March 2020, and May 2021. We took a rigorous inductive, qualitative descriptive approach to characterize how opioid stigma manifests in the lives of patients with advanced cancer.
Patients and their support providers described three primary manifestations of opioid stigma: (1) direct experiences with opioid stigma and discrimination in health care settings (eg, negative, stigmatizing interactions in pharmacies or a pain clinic); (2) concerns about opioid stigma affecting patient care in the future, or anticipated stigma; and (3) opioid-restricting attitudes and behaviors that may reflect internalized stigma and fear of addiction (eg, feelings of guilt).
This qualitative study advances our understanding of opioid stigma manifestations in patients with advanced cancer, as well as coping strategies that patients may use to alleviate their unease (eg, minimizing prescription opioid use, changing clinicians, and distancing from perceptions of addiction). In recognition of the costs of undermanaged cancer pain, it is important to consider innovative treatment strategies to address opioid stigma and improve pain management for patients with advanced cancer. Future research should examine opportunities to build an effective, multilevel opioid stigma intervention targeting patients, clinicians, and health care systems.
围绕处方类阿片(即)的污名化现象日益受到关注,这被认为是有效且符合指南的癌症疼痛管理的障碍。晚期癌症患者报告的疼痛和处方类阿片暴露率较高,但人们对阿片类药物污名化如何在这一人群中表现知之甚少。
我们在 2020 年 3 月至 2021 年 5 月期间对 20 名晚期癌症患者和 11 名支持提供者进行了深入的定性访谈。我们采取严格的归纳、定性描述方法,描述了阿片类药物污名化在晚期癌症患者生活中的表现。
患者及其支持提供者描述了阿片类药物污名化的三种主要表现形式:(1)在医疗保健环境中直接经历的阿片类药物污名化和歧视(例如,在药店或疼痛诊所的负面、污名化的互动);(2)对未来影响患者护理的阿片类药物污名化的担忧,或预期的污名化;(3)限制阿片类药物的态度和行为,这可能反映了内化的污名化和对成瘾的恐惧(例如,感到内疚)。
这项定性研究增进了我们对晚期癌症患者阿片类药物污名化表现的理解,以及患者可能用来减轻不安的应对策略(例如,尽量减少处方类阿片类药物的使用、更换医生,以及远离对成瘾的看法)。鉴于癌症疼痛管理不足的代价,考虑创新的治疗策略来解决阿片类药物污名化问题并改善晚期癌症患者的疼痛管理非常重要。未来的研究应探讨针对患者、临床医生和医疗保健系统的有效、多层次阿片类药物污名化干预措施的机会。